We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
UCB plans to submit marketing applications for Cimzia in psoriatic arthritis and axial spondyloarthritis (AxSpA), including ankylosing spondylitis, to the FDA and EU by the end of the year.
Read More
U.S. manufacturers looking to import their drugs to Latin America are finding that the greatest challenges are capacity-related, as more narrow-bodied aircraft are now flying south, an expert says.
Read More
In an effort to increase transparency, Health Canada says it will begin publishing administrative information on clinical trials that have received a No Objection Letter pursuant to a clinical trial application.
Read More
The Federal Circuit Bar Association urged the Federal Circuit to rehear a patent infringement dispute involving Smith & Nephew Inc. and West Forrest University Health Sciences, saying the court should clarify its role in reviewing obviousness and nonobviousness determinations in patent cases tried before juries.
Read More
GlaxoSmithKline’s ViiV Healthcare agreed to buy the rights to HIV treatments the unit has developed with Shionogi, giving the Japanese drugmaker a 10 percent stake in ViiV as the companies prepare to seek approval of the most advanced medicine from the collaboration.
Read More
Needham-based immunotherapy company Celldex Therapeutics announced positive results from a Phase I study involving its solid tumor cancer vaccine, CDX-1401, in combination with two other drugs.
Read More
A publicly financed $3 billion effort to spur innovative cancer research, reduce cancer rates and speed up the commercialization of new treatments has floundered amid controversy after the mass resignation of nearly three dozen scientists, including two Nobel laureates, from review committees.
Read More